Ipamorelin + GHK-Cu Stack: Complete Protocol

What Are These Two Peptides and Why Stack Them?

Ipamorelin and GHK-Cu act through entirely separate receptor systems, which is exactly why combining them makes biological sense. Ipamorelin binds the ghrelin receptor (GHS-R1a) to trigger pulsatile growth hormone release from the anterior pituitary. GHK-Cu works downstream of GH signaling, directly activating collagen and elastin gene transcription while suppressing inflammatory cytokines. Because neither peptide competes for the same receptor or metabolic pathway, the combination does not create pharmacological antagonism.

Ipamorelin: Mechanism and Evidence Base

Ipamorelin is a pentapeptide GHRP with high selectivity for the GHS-R1a receptor. Unlike older GHRPs such as GHRP-6, ipamorelin does not meaningfully raise cortisol or prolactin at clinical doses, a selectivity profile documented in early pharmacology studies [1]. In a controlled study published in Growth Hormone and IGF Research, ipamorelin produced a GH pulse comparable to GHRH with no significant ACTH or cortisol elevation [2].

Pulsatile GH release from ipamorelin drives downstream IGF-1 production in the liver. IGF-1 in turn promotes protein synthesis, lipolysis in adipose tissue, and collagen deposition in connective tissue [3]. This makes ipamorelin a logical foundation for a stack targeting body composition and tissue repair.

GHK-Cu: Mechanism and Evidence Base

GHK-Cu is a naturally occurring human tripeptide (glycine-histidine-lysine) that binds copper ions with high affinity. Plasma concentrations of GHK decline from roughly 200 ng/mL at age 20 to below 80 ng/mL by age 60 [4]. That age-related decline coincides with reduced wound-healing capacity and slower collagen turnover.

Research by Pickart and colleagues identified GHK-Cu as a broad gene-expression modulator. A 2012 analysis found GHK influences the expression of at least 31 genes involved in collagen synthesis, antioxidant response, and DNA repair [5]. Separately, in-vitro work confirmed GHK-Cu stimulates synthesis of types I and III collagen, decorin, and glycosaminoglycans in human fibroblasts [6].

Why These Two Pathways Complement Each Other

Ipamorelin raises systemic GH and IGF-1, creating an anabolic environment. GHK-Cu then acts locally at the tissue level, directing fibroblasts, keratinocytes, and potentially satellite cells to use that anabolic signal for structural repair. Think of ipamorelin as raising the ceiling on repair capacity and GHK-Cu as the contractor that shows up to do the actual renovation work.

Dosing Protocol for the Ipamorelin + GHK-Cu Stack

Ipamorelin Dosing

The standard clinical range for ipamorelin runs from 100 mcg to 300 mcg per injection. Most practitioners start patients at 150 mcg once nightly, injected subcutaneously 30 to 60 minutes before sleep to align with the physiological nocturnal GH surge [7]. After 2 to 4 weeks, dosing can advance to twice daily (morning fasted and pre-sleep) if tolerability is confirmed and IGF-1 levels have been checked.

Doses above 300 mcg per injection have not been shown to produce proportionally greater GH release. The GH response to GHS-R1a agonists is saturable, meaning 300 mcg likely approaches the ceiling for most adults [1].

GHK-Cu Dosing

Subcutaneous GHK-Cu is typically dosed at 1 to 2 mg once daily, injected into the abdomen or thigh. Some protocols extend to 3 mg daily in the context of significant wound healing or post-procedure recovery, though human dose-escalation data above 2 mg remain limited to case series and practitioner reports.

Topical GHK-Cu (0.1%, 1% formulations) can run concurrently with subcutaneous ipamorelin without any known interaction. The two delivery routes serve different compartments: topical targets dermal fibroblasts directly, subcutaneous reaches systemic circulation.

Injection Timing and Site Rotation

| Time of Day | Peptide | Dose | Route | |---|---|---|---| | Morning (fasted) | Ipamorelin | 150 mcg | Subcutaneous | | Morning (fasted) | GHK-Cu | 1 to 2 mg | Subcutaneous | | Pre-sleep (fasted 2 hrs) | Ipamorelin | 150 mcg | Subcutaneous |

Inject GHK-Cu and ipamorelin at different anatomical sites to simplify tracking and minimize local tissue irritation. Rotate among abdomen, lateral thigh, and deltoid region. Do not inject within 2 cm of a previous site until at least 48 hours have passed.

Cycle Length

Most practitioners run this stack for 8 to 12 weeks followed by a 4-week off period. The rationale mirrors standard peptide cycling logic: continuous GHS-R1a stimulation may downregulate receptor sensitivity over time, analogous to patterns seen with GH secretagogues in rodent models [8]. GHK-Cu does not appear to cause receptor desensitization, so some clinicians continue topical GHK-Cu through the off cycle.

Laboratory Monitoring During the Stack

Baseline labs before starting any GH secretagogue stack should include IGF-1, fasting glucose, HbA1c, and a basic metabolic panel. The Endocrine Society's clinical practice guideline on GH deficiency specifies IGF-1 as the primary biomarker for monitoring GH axis activity [9].

IGF-1 Targets

Aim to keep IGF-1 within the age- and sex-adjusted reference range, typically the 50th, 75th percentile for age. Supraphysiologic IGF-1 (above the 97th percentile) raises theoretical concern for insulin resistance and cell proliferation. Check IGF-1 at 6 to 8 weeks after starting ipamorelin. If levels exceed the upper reference limit, reduce the ipamorelin dose by 50 mcg per injection.

Glucose Monitoring

GH is a counter-regulatory hormone. High-dose GH secretagogues can blunt insulin sensitivity in susceptible individuals [10]. Fasting glucose and HbA1c at baseline and at the 8-week mark are the minimum standard. Patients with prediabetes (fasting glucose 100 to 125 mg/dL) warrant monthly fasting glucose checks.

Copper Status for GHK-Cu

GHK-Cu delivers a small but real copper payload. Serum copper and ceruloplasmin at baseline are advisable for anyone with hepatic disease or suspected Wilson disease before initiating subcutaneous GHK-Cu. For most healthy adults receiving 1 to 2 mg daily, copper accumulation is not considered clinically significant based on the pharmacokinetic modeling available [5].

Evidence Quality and Gaps

This stack lacks a published randomized controlled trial. That gap is real, and patients deserve to know it upfront.

What the Data Actually Show

Ipamorelin's GH-releasing effects are supported by controlled pharmacology studies in humans [2]. GHK-Cu's effects on collagen gene expression are supported by in-vitro human fibroblast studies and some in-vivo animal wound-healing models [6]. A 2010 paper in Wound Repair and Regeneration reported accelerated wound closure in a rat model treated with GHK-Cu, with histology showing increased collagen fiber density at day 14 [11].

The Endocrine Society notes that peptides targeting the GH axis "require further clinical investigation before routine use can be recommended outside of defined deficiency states" [9]. That statement applies to ipamorelin as a class.

What Remains Unknown

No published study has measured the combined effect of ipamorelin plus GHK-Cu on any human outcome, whether body composition, skin quality, wound healing, or IGF-1 kinetics. Synergistic or additive effects are plausible based on mechanism but remain unverified. Practitioners synthesizing outcomes from patient cohorts report subjective improvements in skin texture and recovery time within 6 to 8 weeks, but these reports carry selection bias and no control arm.

Contraindications and Safety Considerations

Absolute Contraindications

Do not use ipamorelin in active malignancy. GH and IGF-1 can promote growth-factor-dependent tumor proliferation. The FDA has not approved ipamorelin for any indication; it is available only through licensed compounding pharmacies under a valid prescription [12]. Patients with a personal or first-degree family history of pituitary adenoma, acromegaly, or IGF-1-driven cancers (breast, prostate, colorectal) should avoid GH secretagogues unless supervised by an endocrinologist.

Relative Contraindications and Cautions

• Uncontrolled type 2 diabetes: GH counter-regulation may worsen glycemic control.
• Pregnancy and breastfeeding: no human safety data exist for either peptide.
• Wilson disease or copper overload states: GHK-Cu carries a copper payload.
• Age <18: GH axis manipulation in skeletally immature patients carries unknown risks.

Common Side Effects

Ipamorelin's most reported side effect is mild, transient flushing or a warm sensation immediately after injection, likely from transient vasodilation rather than histamine release. Water retention at higher doses (above 300 mcg) is reported anecdotally. GHK-Cu injections can cause temporary local erythema at the injection site, which typically resolves within 2 hours.

Sourcing and Compounding Considerations

Ipamorelin in the United States is available only through 503A or 503B compounding pharmacies with a valid prescription. The FDA's 2023 guidance on compounded peptides placed several GHRPs on the list of bulk drug substances under review, and the regulatory status of ipamorelin is subject to change [12]. Verify with your prescribing clinician that the compounding pharmacy holds current PCAB accreditation and performs USP <797> sterility testing on all injectable preparations.

GHK-Cu for injection must similarly come from an accredited compounding pharmacy. Cosmetic topical GHK-Cu products (serums, creams) are sold over the counter, but their bioavailability compared to injectable preparations has not been formally characterized in peer-reviewed literature.

Always request a certificate of analysis (COA) confirming peptide purity above 98% and absence of endotoxins below 5 EU/mg before injecting any compounded peptide.

Who Is a Reasonable Candidate for This Stack?

The patient profile that most practitioners describe as suitable for this stack shares several characteristics: age 35 or older with documented low-normal IGF-1 (below the 25th percentile for age), interest in skin quality or recovery optimization, no active or recent malignancy, and willingness to complete baseline and follow-up labs.

Patients seeking this stack primarily for performance enhancement without any lab-confirmed GH axis deficit occupy a higher-uncertainty category. The benefit-to-risk calculation is harder to make, and a conservative prescriber may reasonably decline.

Patients already on GHRH analogs such as sermorelin or tesamorelin should not add ipamorelin without direct prescriber supervision. Combining two GH-axis stimulants raises IGF-1 non-linearly and increases the risk of supraphysiologic IGF-1 levels.

Practical Reconstitution and Storage

Lyophilized (freeze-dried) ipamorelin typically arrives in 2 mg or 5 mg vials. Reconstitute with bacteriostatic water (0.9% benzyl alcohol in sterile water) at a volume that yields a convenient per-dose concentration. A common approach: add 2 mL bacteriostatic water to a 2 mg vial to get 1,000 mcg/mL, making a 150 mcg dose equal to 0.15 mL on a standard insulin syringe.

Store reconstituted ipamorelin refrigerated at 2 to 8°C. Use within 28 days of reconstitution. GHK-Cu reconstituted solutions follow the same storage parameters. Never freeze a reconstituted peptide solution; ice crystal formation degrades the peptide structure.

Draw ipamorelin and GHK-Cu into separate syringes unless your prescribing compounding pharmacy has confirmed stability of a premixed preparation in writing.